INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1

CUSIP: 45845PAB4

Q3 2023 13F Holders as of 30 Sep 2023

Type / Class
Debt / NOTE 2.000% 5/1
Market price (% of par)
98.35%
Total 13F principal
$69,639,076
Principal change
+$24,792,846
Total reported market value
$91,099,758
Number of holders
13
Value change
+$27,093,668
Number of buys
6
Number of sells
2

Quarterly Holders Quick Answers

What is CUSIP 45845PAB4?
CUSIP 45845PAB4 identifies 45845PAB4 - INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 as of Q3 2023

As of 30 Sep 2023, INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 was held by 13 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $69,639,076 in principal (par value) of the bond. The largest 10 bondholders included FRANKLIN RESOURCES INC, Weiss Asset Management LP, OAKTREE CAPITAL MANAGEMENT LP, AQR Arbitrage LLC, Calamos Advisors LLC, Anson Funds Management LP, UBS ASSET MANAGEMENT AMERICAS INC, SYQUANT CAPITAL SAS, Skaana Management L.P., and Russell Investments Group, Ltd.. This page lists 13 institutional bondholders reporting positions for the Q3 2023 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.